Indivior Pharmaceuticals, Inc. (INDV) fair value analysis
Nasdaq · Updated 2026-10-19
INDV price how computed
Forward Fair Value verdict
UndervaluedINDV is trading at more than a 25% discount to estimated fair value.
Based on TickrTrends' weekly Forward Fair Value model.
- Last price
- $32.45
- Sector
- Healthcare
- 12-month range
- $24.78–$41.83
- Market cap
- $3.83B
- From 52-week high
- -22.4%
- Shares outstanding
- 118M
- Rank in Healthcare by discount to fair value
- #17 of 108
Last price is our stored weekly price from 2026-10-16, older than the 2026-10-19 run that built this page; the chart runs through 2026-10-16.
Indivior Pharmaceuticals, Inc. is a specialty pharmaceutical company that focuses on developing and commercializing medications for addiction, pain, and other therapeutic areas. The company operates globally with a presence in multiple countries to manufacture, market, and distribute its pharmaceutical products.
INDV currently ranks #17 of 108 Healthcare stocks by discount to fair value. It has screened as Undervalued for 14 consecutive weekly runs.
Fundamentals (4 quarters) how computed
- Market cap
- $3.83B
- P/E (trailing)
- 9x
- Revenue (TTM)
- $1.33B
- Net margin
- 26.7%
- EPS (TTM)
- $3.65
- Gross margin
- 85.7%
- Debt / equity
- 0.00
- Revenue growth (3-yr avg)
- 8.9%
- Shares outstanding
- 118M
Derived indicators how computed
- Quality grade
- F
- Margin trend
- Stable
- 52-week position
- The lower-middle quarter of its range
Technicals how computed
- RSI (14-day)
- 31 · neutral
- 50-day average
- $35.98
- 200-day average
- $35.69
- Moving-average state
- 50-day above 200-day (golden cross state); price between the averages
Dividends how computed
- Dividend
- None in the last 12 months (last ex-date 2016-06-16)
Earnings how computed
- Next earnings report
- 2026-10-29
- Last 8 quarters vs consensus
- 7 beat, 1 missed
- Quarter by quarter
- 2026-06 ▲ beat (+18.6%)
2026-03 ▲ beat (+45.5%)
2025-12 ▲ beat (+26.2%)
2025-09 ▲ beat (+75.6%)
2025-06 ▲ beat (+104.0%)
2025-03 ▲ beat (+78.3%)
2024-12 ▲ beat (+22.7%)
2024-09 ▼ miss (-90.3%)
Analyst consensus how computed
This is not TickrTrends' verdict.
- Analyst ratings
- 6 buy · 0 hold · 0 sell (6 analysts)
- Consensus lean
- Buy-leaning
- Consensus price target
- $49
- Target vs last price
- +51.0%
What our data shows for INDV
- Our model validated 13 trailing price-to-earnings windows for INDV, built from quarterly earnings records.
- Shares are trading in the middle of their 12-month price range of $24.78–$41.83.
- The 14-day relative strength index sits at a neutral 31.
The exact numbers are one step away
- The precise Forward Fair Value dollar figure for INDV
- Exact discount / premium to today's price
- The normalized historical P/E behind the estimate, and how many quarters support it
- Forward EPS input and fiscal-year basis
- Screeners and rankings across the full S&P 500 and Nasdaq universes
Forward Fair Value applies a conservatively normalized historical price-to-earnings multiple to the consensus earnings estimate for the next full fiscal year; how TickrTrends computes it.
What people are saying
Follow the INDV conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-10-19 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-12 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-11 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-10 — TickrTrends' derived indicators for INDV show a deterioration in quality assessment this week, with the quality grade declining from C to F. The stock remains classified as undervalued according to the current valuation verdict. This significant downgrade in quality metrics suggests a meaningful shift in the underlying fundamentals tracked by the service's indicators.
- 2026-10-05 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-28 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-21 — INDV's technical positioning improved this week as its relative strength index moved from oversold territory into neutral zone. The stock maintains an undervalued valuation verdict based on TickrTrends' derived indicators. This shift in RSI suggests reduced downward momentum in the healthcare sector stock.
- 2026-09-17 — No material change this week: the verdict, bands and grades all held steady.
Frequently asked questions
Is INDV stock undervalued?
Based on TickrTrends' Forward Fair Value model (updated 2026-10-19), INDV is trading at more than a 25% discount to estimated fair value and screens as undervalued. The exact fair value and discount are available to subscribers.
What is INDV's TickrTrends verdict?
INDV's current verdict is Undervalued, refreshed with every weekly Forward Fair Value run.
How does INDV compare to other Healthcare stocks?
INDV ranks #17 of 108 Healthcare stocks in TickrTrends' coverage by discount to fair value.
Is INDV overbought or oversold?
INDV's 14-day RSI is in neutral territory - neither overbought nor oversold.
Does INDV pay a dividend?
INDV has paid no dividend in the last twelve months; its last ex-dividend date on file was 2016-06-16.
When does INDV report earnings next?
INDV's next earnings report is scheduled for 2026-10-29, per the published earnings calendar.
Does INDV usually beat earnings estimates?
Over its last 8 reported quarters INDV beat the consensus estimate 7 times and missed 1 times, by TickrTrends' comparison of reported and estimated EPS.
What do analysts say about INDV?
Of 6 analysts covering INDV, 6 rate it a buy, 0 a hold and 0 a sell - buy-leaning, with a consensus price target of $49 (+51.0% versus TickrTrends' last price). This is the analyst consensus, not TickrTrends' Forward Fair Value verdict.
More in Healthcare
Head-to-head comparisons
INDV vs AXSM · INDV vs DXCM · INDV vs GEHC · INDV vs IDXX · INDV vs ISRG